Targeting Clever-1 in Macrophage-Driven Disease: Clinical Lessons from MDS & Beyond
Time: 5:00 pm
day: Conference Day One
Details:
- MDS and AML are cancers of the macrophage lineage, in which all cancer cells express Clever-1, a master receptor of immunosuppression on macrophages
- Targeting Clever-1 in MDS has proven extremely effective to overcome treatment resistance to standard of care agents
- Clever-1 is found on TAMs in a number of aggressive and treatment resistant cancers and targeting Clever-1 may prove beneficial to overcome treatment resistance in a number of different cancers
Speakers:
